Global Pharma 2014
Dr. Brian W Tempest
www.briantempest.com
Mumbai
August 2014
Hale & Tempest
Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on
their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia
and India where he has lived for the last decade.
Brian is the Editor of the prestigious Journal of Generic Medicines. Previously he has worked for
Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive
Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008 when he retired.
He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result
has a valuable insight into India. Brian has also worked for Glaxo as Regional Director Far East and
Regional Director Middle East & Africa from 1985 to 1992.
Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare
businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan
and India. He has also led many sessions at Investor Meetings held around the world from Tokyo to
Las Vegas.
He is now a Non Executive Director of Religare Capital Markets, Fortis Healthcare, SRL Diagnostics
and Glenmark Pharmaceuticals. Brian speaks at global conferences and more information on these
presentations can be found on his website www.briantempest.com.
Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became
Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a
Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a
Chartered Chemist. He is now Chairman and owner of Hale & Tempest Co Ltd
Hale & Tempest
Global Healthcare Spend to 2025 +6%
source: Meet Novartis Management June 17 2014
Hale & Tempest
Pharma Market to2020
source: Evaluate June 1 2014
Hale & Tempest
USA New Product Pipeline
source: Evaluate June 1 2014
Hale & Tempest
Access to Medicines – 4% for 47%
source: WHO June 2014
Hale & Tempest
Affordability of Simple Medicines
source: WHO, 26 June 2014
Hale & Tempest
Sovaldi (Gilead)- $1k pill costs $11
source: FT July 31 2014
Hale & Tempest
Unfortunate Comments
source: February 2 2014 Bayer
Hale & Tempest
Emerging Markets Top 10 Pharma Cos
source: Fierce Pharma 10 October 2013
Hale & Tempest
Global Patent Cliff to 2020
source: Evaluate June 1 2014
Hale & Tempest
US - India Pharma Market Share
source: Meet Novartis Management June 17 2014
Hale & Tempest
Top 22 Generic Companies
source: Generics Bulletin 20 June 2014, 5 India, 1 Japan
Hale & Tempest
Next 22 Generic Companies
source: Generics Bulletin 20 June 2014, 8 India, 2 Japan
Hale & Tempest
Strength of Local Companies
source: IMS May 2012
Hale & Tempest
GDP 2028 $b
source: Centre for Economics and Business research 2013
Hale & Tempest
Teva versus Actavis and Mylan
source: Motley Fool Jul 21 2014
Hale & Tempest
Actavis Value via M&A
source: EGA, June 2014
Hale & Tempest
Shareholder Return from Indian Pharma
source: McKinsey , EGA June 2014
Hale & Tempest
Stada Focus to Russia from Germany
source: Generics Bulletin April 4 2014 ,Stada
Hale & Tempest
USA Unsustainable Pricing
source: Express Scripts, FT July 31 2014
Hale & Tempest
Falsified Medicines – including thefts
source: EGA June 2014, Advice on Implementation of EU Directive 2011/62/EU
Hale & Tempest
EU Falsified Medicines Directive - Costs
source: EGA June 2014
Hale & Tempest
EU Falsified Medicines Directive
source: Aegate EGA June 2014
Hale & Tempest
EU Falsified Medicines Directive
source: Domino, EGA June 2014
Hale & Tempest
Valeant – “a house of cards”
source: FT June 16 2014
Hale & Tempest
Sandoz - “excluding Germany”
source: Meet Novartis Management June 17 2014
Hale & Tempest
Ranbaxy top 2 products Rx OTC switch
source: IMS 2013/2014
Hale & Tempest
EU versus USA Factory Inspections
source: Reuters, June 5 2014
Hale & Tempest
Big Pharma Shuffle
source: FT
Hale & Tempest
Acquisition, Divestment & Spin Offs
in 2014 valued at $220b from 2012 $50b
•Novartis - divested Blood Diagnostics, Animal Health to
Lilly, OTC, Vaccines and gained GSK Oncology
•Bayer - Bayer Material Sciences likely sale, buying
Merck OTC to become 2nd in OTC
•Pfizer - Nutrition & Zoetis Animal Health divested but
may bid for GSK, acquired Innopharm
•GSK - divest tail products, drinks brands, oncology
brands and acquired vaccines and OTC to become1st
•Teva - looking for large acquisition
•Shire - buys ViroPharma, bought by Abbvie
•Mylan – buying Abbott mature brands
•Merck - mature brands & animal health for sale
•GSK & Sanofi - old brands for sale, NEW STRATEGY
Hale & Tempest
•Valeant - bidding for Allergan
•Sun - buying Ranbaxy, bought Pharmalucence
Open letter to Barroso from the Chairman
of INEOS (Jim Radcliffe) on 7 March 2014
Hale & Tempest
Europe - Impact of Recession on Health
source: OECD Health data 2014
Hale & Tempest
India New Government
Hale & Tempest
Modi –the Strongman
Source: Economist 24 May 2014
Hale & Tempest
External View of India New PM
source: International New York Times June 2 2014
Hale & Tempest
Modi accelerating Development
Source: Ft 21 May 2014
Hale & Tempest
Thank You
brian.tempest@clara.co.uk
www.briantempest.com
Hale & Tempest